NS-398
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 522677

CAS#: 123653-11-2

Description: NS-398 is a selective inhibitor of cyclooxygenase-2 (COX-2). NS-398 Inhibits Choroidal Neovascularization and Subretinal Fibrosis. NS-398 enhances the efficacy of bortezomib against RPMI8226 human multiple myeloma cells. NS-398 inhibits proliferation and induces apoptosis in human osteosarcoma cells via downregulation of the survivin pathway. NS-398-enhanced apoptosis of esophageal carcinoma cell EC9706 by adjusting expression of survivin and caspase-3.


Price and Availability

Size
Price

10mg
USD 110
100mg
USD 350
1g
USD 1450
Size
Price

25mg
USD 150
200mg
USD 550
2g
USD 2450
Size
Price

50mg
USD 250
500mg
USD 850
5g
Ask price

NS-398, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 522677
Name: NS-398
CAS#: 123653-11-2
Chemical Formula: C13H18N2O5S
Exact Mass: 314.0936
Molecular Weight: 314.356
Elemental Analysis: C, 49.67; H, 5.77; N, 8.91; O, 25.45; S, 10.20


Synonym: NS-398; NS 398; NS398.

IUPAC/Chemical Name: N-[2-(cyclohexyloxy)-4-nitrophenyl]-methanesulfonamide

InChi Key: KTDZCOWXCWUPEO-UHFFFAOYSA-N

InChi Code: InChI=1S/C13H18N2O5S/c1-21(18,19)14-12-8-7-10(15(16)17)9-13(12)20-11-5-3-2-4-6-11/h7-9,11,14H,2-6H2,1H3

SMILES Code: CS(=O)(NC1=CC=C([N+]([O-])=O)C=C1OC2CCCCC2)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Zhang R, Liu Z, Zhang H, Zhang Y, Lin D. The COX-2-Selective Antagonist (NS-398) Inhibits Choroidal Neovascularization and Subretinal Fibrosis. PLoS One. 2016 Jan 13;11(1):e0146808. doi: 10.1371/journal.pone.0146808. eCollection 2016. PubMed PMID: 26760305; PubMed Central PMCID: PMC4711821.

2: Kim J, Shim M. COX-2 inhibitor NS-398 suppresses doxorubicin-induced p53 accumulation through inhibition of ROS-mediated Jnk activation. Mol Carcinog. 2016 Jan 12. doi: 10.1002/mc.22458. [Epub ahead of print] PubMed PMID: 26756900.

3: Retraction Note to: Effect of NS-398, a cyclooxygenase-2 selective inhibitor, on the cytotoxicity of cytotoxic T lymphocytes to ovarian carcinoma cells. Tumour Biol. 2015 Sep;36(9):7297. doi: 10.1007/s13277-015-3694-6. PubMed PMID: 26281984.

4: Trandafir CC, Pouliot WA, Dudek FE, Ekstrand JJ. Co-administration of subtherapeutic diazepam enhances neuroprotective effect of COX-2 inhibitor, NS-398, after lithium pilocarpine-induced status epilepticus. Neuroscience. 2015 Jan 22;284:601-10. doi: 10.1016/j.neuroscience.2014.10.021. Epub 2014 Oct 18. PubMed PMID: 25453777; PubMed Central PMCID: PMC4326254.

5: Que W, Li S, Chen J. NS-398 enhances the efficacy of bortezomib against RPMI8226 human multiple myeloma cells. Mol Med Rep. 2013 May;7(5):1641-5. doi: 10.3892/mmr.2013.1394. Epub 2013 Mar 26. PubMed PMID: 23545701.

6: Wang X, Liang Y, Wang J, Wang M. Effect of NS-398, a cyclooxygenase-2 selective inhibitor, on the cytotoxicity of cytotoxic T lymphocytes to ovarian carcinoma cells. Tumour Biol. 2013 Jun;34(3):1517-22. doi: 10.1007/s13277-013-0677-3. Epub 2013 Mar 1. Retraction in: Wang X, Liang Y, Wang J, Wang M. Tumour Biol. 2015 Aug;36(9):7297. PubMed PMID: 23456767.

7: Tunctan B, Sari AN, Kacan M, Unsal D, Buharalioglu CK, Sahan-Firat S, Korkmaz B, Falck JR, Malik KU. NS-398 reverses hypotension in endotoxemic rats: contribution of eicosanoids, NO, and peroxynitrite. Prostaglandins Other Lipid Mediat. 2013 Jul-Aug;104-105:93-108. doi: 10.1016/j.prostaglandins.2012.08.007. Epub 2012 Sep 5. PubMed PMID: 22975359; PubMed Central PMCID: PMC3774147.

8: Duan DP, Dang XQ, Wang KZ, Wang YP, Zhang H, You WL. The cyclooxygenase-2 inhibitor NS-398 inhibits proliferation and induces apoptosis in human osteosarcoma cells via downregulation of the survivin pathway. Oncol Rep. 2012 Nov;28(5):1693-700. doi: 10.3892/or.2012.1992. Epub 2012 Aug 24. PubMed PMID: 22922684.

9: Sugiyama T, Meakin LB, Galea GL, Lanyon LE, Price JS. The cyclooxygenase-2 selective inhibitor NS-398 does not influence trabecular or cortical bone gain resulting from repeated mechanical loading in female mice. Osteoporos Int. 2013 Jan;24(1):383-8. doi: 10.1007/s00198-012-1922-0. Epub 2012 Feb 14. PubMed PMID: 22349912; PubMed Central PMCID: PMC3536947.

10: Vecchio AJ, Malkowski MG. The structure of NS-398 bound to cyclooxygenase-2. J Struct Biol. 2011 Nov;176(2):254-8. doi: 10.1016/j.jsb.2011.07.019. Epub 2011 Aug 6. PubMed PMID: 21843643; PubMed Central PMCID: PMC3185125.

11: Lee SM, Gai WW, Cheung TK, Peiris JS. Antiviral activity of a selective COX-2 inhibitor NS-398 on avian influenza H5N1 infection. Influenza Other Respir Viruses. 2011 May;5 Suppl 1:230-2. PubMed PMID: 21761591.

12: Banu NA, Daly RS, Buda A, Moorghen M, Baker J, Pignatelli M. Reduced tumour progression and angiogenesis in 1,2-dimethylhydrazine mice treated with NS-398 is associated with down-regulation of cyclooxygenase-2 and decreased beta-catenin nuclear localisation. Cell Commun Adhes. 2011 Feb;18(1-2):1-8. doi: 10.3109/15419061.2011.586754. Epub 2011 Jun 16. PubMed PMID: 21679035.

13: Li S, Tian D, Fei P, Gao Y, Chen Z, Wang Q, Tong Q. A cyclooxygase-2 inhibitor NS-398-enhanced apoptosis of esophageal carcinoma cell EC9706 by adjusting expression of survivin and caspase-3. Cancer Invest. 2011 Feb;29(2):102-6. PubMed PMID: 21329005.

14: Li N, Che CY, Hu LT, Lin J, Wang Q, Zhao GQ. Effects of COX-2 inhibitor NS-398 on IL-10 expression in rat fungal keratitis. Int J Ophthalmol. 2011;4(2):165-9. doi: 10.3980/j.issn.2222-3959.2011.02.11. Epub 2011 Apr 18. PubMed PMID: 22553634; PubMed Central PMCID: PMC3340712.

15: Tunctan B, Korkmaz B, Cuez T, Kemal Buharalioglu C, Sahan-Firat S, Falck J, Malik KU. Contribution of vasoactive eicosanoids and nitric oxide production to the effect of selective cyclooxygenase-2 inhibitor, NS-398, on endotoxin-induced hypotension in rats. Basic Clin Pharmacol Toxicol. 2010 Nov;107(5):877-82. doi: 10.1111/j.1742-7843.2010.00589.x. PubMed PMID: 22545970; PubMed Central PMCID: PMC3128812.

16: Youns M, Efferth T, Hoheisel JD. Transcript profiling identifies novel key players mediating the growth inhibitory effect of NS-398 on human pancreatic cancer cells. Eur J Pharmacol. 2011 Jan 10;650(1):170-7. doi: 10.1016/j.ejphar.2010.10.026. Epub 2010 Oct 20. PubMed PMID: 20969859.

17: Lee SY, Lee MY, Park SH, Kim TH, Moon YT, Han JH, Myung SC. NS-398 (a selective cyclooxygenase-2 inhibitor) decreases agonist-induced contraction of the human ureter via calcium channel inhibition. J Endourol. 2010 Nov;24(11):1863-8. doi: 10.1089/end.2009.0461. Epub 2010 Oct 19. PubMed PMID: 20958135.

18: Fernández-Martínez AB, Bajo AM, Valdehita A, Isabel Arenas M, Sánchez-Chapado M, Carmena MJ, Prieto JC. Multifunctional role of VIP in prostate cancer progression in a xenograft model: suppression by curcumin and COX-2 inhibitor NS-398. Peptides. 2009 Dec;30(12):2357-64. doi: 10.1016/j.peptides.2009.09.018. Epub 2009 Sep 20. PubMed PMID: 19772879.

19: Liu JF, Zhu GJ, Jamieson GG, Wu TC, Zhu TN, Shan BE, Drew PA. NS-398 induces apoptosis in human esophageal cancer cells through inhibition of NF-kappaB downstream regulation of cyclooxygenase-2. Cancer Invest. 2009 Jan;27(1):17-23. doi: 10.1080/07357900801992913. PubMed PMID: 19160097.

20: John-Aryankalayil M, Palayoor ST, Cerna D, Falduto MT, Magnuson SR, Coleman CN. NS-398, ibuprofen, and cyclooxygenase-2 RNA interference produce significantly different gene expression profiles in prostate cancer cells. Mol Cancer Ther. 2009 Jan;8(1):261-73. doi: 10.1158/1535-7163.MCT-08-0928. PubMed PMID: 19139136; PubMed Central PMCID: PMC2861287.